ArticleBreast cancer research : BCR2026
[
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prospective comparison of [European journal of nuclear medicine and molecular imaging · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background[68Ga]Ga-labeled fibroblast activation protein inhibitor ([68Ga]Ga-FAPI) PET/CT has shown promising potential in predicting pathological complete response (pCR) in patients with breast cancer (BC). However, current literature lacks comprehensive data addressing molecular subtype-specific variations. This study aims to evaluate the predictive value of [68Ga]Ga-FAPI-04 PET/CT across different BC molecular subtypes.
methodsThis preliminary study enrolled 66 patients with clinical stage II-III BC scheduled for neoadjuvant chemotherapy (NAC). Patients underwent [68Ga]Ga-FAPI-04 PET/CT at baseline (PET1), after two NAC cycles (PET2), and presurgery (PET3). The maximum standardized uptake value (SUVmax) and its percentage change from baseline (ΔSUVmax) were calculated for the primary tumors. Pathological response was assessed postsurgery. Patients were stratified into three molecular subtypes: hormone receptor-positive/HER2-negative (HR+/HER2−), HER2-positive (HER2+), and triple-negative breast cancer (TNBC). Receiver operating characteristic (ROC) curve analysis was utilized to evaluate the predictive performance of FAPI parameters for pCR.
resultsAmong the 66 patients, 21 (31.8%) achieved pCR, with rates varying significantly across molecular subtypes (P = 0.002). Baseline [68Ga]Ga-FAPI-04 uptake (SUVmax1) was significantly higher in HER2+ tumors (17.98 ± 6.34) compared to HR+/HER2− (14.37 ± 4.11) and TNBC tumors (15.00 ± 5.25) (P = 0.043). The predictive value of [68Ga]Ga-FAPI-04 parameters for pCR was highly dependent on molecular subtype. In HER2+ tumors, early response assessment was most effective, with ΔSUVmax1 (change after two cycles) being the strongest predictor (area under the curve [AUC] = 0.799). A cutoff of − 69.49% yielded 85.7% sensitivity and 72.7% specificity. For TNBC, late-phase parameters demonstrated exceptional accuracy, with SUVmax3 (presurgery) achieving near-perfect discrimination (AUC = 0.967). A cutoff of ≤ 2.19 provided 100% sensitivity and 95.5% specificity. In HR+/HER2− tumors, late-phase parameters were most predictive, with SUVmax3 showing excellent performance (AUC = 0.948). A cutoff of ≤ 1.58 yielded 75.0% sensitivity and 91.7% specificity.
conclusionThe predictive efficacy of [68Ga]Ga-FAPI-04 PET/CT for pCR demonstrates substantial variability across BC molecular subtypes. These findings underscore the potential of [68Ga]Ga-FAPI-04 PET/CT to inform subtype-specific, personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.